Newsletter

Neurology poster at the AFSSI Connexions 2025   ETAP-Lab will be present at the AFSSI Connexions 2025 in Toulouse on July 1 and 2 to present the poster resulting from the research work of the laboratory dedicated to Neurology and Neurodegenerative Diseases.   Healthcare R&D and Innovation: French preclinical CROs at the heart of European leadership AFSSI (the French Association of Service and Innovation Companies), in partnership with AD'OCC, the Occitanie region's economic development agency, is organizing the 12ᵉ edition of AFSSI Connexions on July

Preclinical Dermatology - Discover our Poster at SPIN 2025 Congress in Paris ETAP-Lab will be presenting a poster during the next edition of the SPIN 2025 Congress, organized every 3 years by the René Touraine Foundation, focused on Skin Inflammation & Psoriasis diseases. Let's talk inflammation at SPIN with our poster on our reference models using our unique translational approach focused on assessing rodent behavior and well-being. We share an overview of over 10 years of study results, showing just how reproducible

Booth & Partnering at BIO Convention 2025 in Boston   Our team will be at BIO 2025 in Boston (June 16-19), the right spot for Health Innovation! 📌 You can visit us at Booth 1935 with Eurobiomed, you'll meet Jerome Bernard and Sandra Robelet. 📆 We are partnering at BIO Convention 2025. You can connect through the BIO Partnering™ system and book a meeting to explore how we can support you in your drug development as a preclinical CRO.   "As a CRO, we have to

Meet our expert during the poster session As preclinical CRO expert in neuroscience research, we are delighted to participate in the 4th MPS Microphysiology Systems World Summit to present our research poster on our microfluidic platform dedicated to Neurodegenerative diseases (NDDs). When: from June, 9 to 13. Where: Brussels, Belgium. Poster session: Poster Session 4: Thursday June 12 Afternoon - Board 277. Track 2: MPS for Biomedical Research and Disease Modelling. Theme 2.5: Understanding the brain with MPS Dr Valentin TALLANDIER, in vitro Preclinical Project

100% of Customer Satisfaction in 2024 We’re proud to share that in 2024, we achieved a 100% customer satisfaction rate, with an average score of 9.3 out of 10. It's important for us to establish a trustful and long-lasting relationship with our customers. That’s why we asked our customers to evaluate the quality of their collaboration with us throughout the 2024 studies. The results speak for themselves: 100% of respondents reported being fully satisfied with their experience working with ETAP-Lab and our

Dr Ahmad Allouche, Head of in vitro biology, presented the team’s research* during at Venusberg Neuroinflammation Meeting 2025 in Luxembourg in his poster “NEUROINFLAMMATION MODELS OF NEURODEGENERATIVE DISEASES“. Learn more about our cutting-edge platform for target identification & drug discovery in the poster! Until the poster is available here, don’t wait any longer and ask for the poster in PDF!   *Ahmad ALLOUCHE, Valentin TALLANDIER, Léane DIER, Sonia KRIDI, Julie COLIN, Nicolas VIOLLE.

As preclinical CRO expert in AD's and PD's disease research, we are delighted to participate in the 8th Venusberg Meeting on Neuroinflammation.   When: from May, 15th to 17th. Where: on Campus Belval, at University of Luxembourg, in Luxembourg. Poster session: POSTER #2 on May, 15th   🧑‍🔬 Meet our expert during the poster session Dr Ahmad Allouche, Head of in vitro Biology, will be presenting the poster on "Neuroinflammation Models of Neurodegenerative Diseases". Let's meet there to explore our in vitro & in vivo services dedicated to

Le Comité interministériel de l'innovation C2i s'est tenu à Paris le 10 avril 2025, et nous sommes fiers de participer à l'aventure France 2030 pour rapprocher le futur et contribuer à l'excellence française dans la recherche et l’innovation en santé. ETAP-Lab bénéficie depuis plusieurs années du soutien de l'État français pour ses projets d'innovation ambitieux, avec une perspective de croissance significative pour l'entreprise et un rayonnement accru pour la filière biotech française. Nous remercions l’État pour son soutien avec France 2030 pour